China's NMPA Conditional Approval Pathway for Oncology Products
For teams planning oncology submissions in China, conditional approval offers a route to market before a full confirmatory dataset is in hand — but it carries binding post-marketing obligations and firm deadlines. Knowing how the NMPA has actually applied the pathway helps regulatory and clinical groups judge whether a program qualifies and what commitments approval would lock in.
The analysis below sets out where conditional approval sits within China's post-2020 registration framework, the eligibility and evidence standards the NMPA applies, the confirmatory studies and time limits imposed after launch, and the oncology products that have been granted approval through it.
Want to ask Rhizome your own regulatory questions? Try it for free.
China's NMPA conditional approval pathway for oncology products
Conditional approval (附条件批准) is one of the four expedited registration pathways China introduced in its 2020 drug registration reform, alongside breakthrough therapy designation, priority review and approval, and special (emergency) approval 7573. It lets the National Medical Products Administration (NMPA) grant a marketing authorization before a full confirmatory dataset is complete, on the understanding that the holder will finish the required studies after launch 75. Oncology has been the pathway's most active therapeutic area, because advanced-cancer settings routinely combine a serious, life-threatening disease, an unmet need, and endpoints (tumor response, progression-free survival) that can be read out well before overall survival matures.
Where the pathway sits in the registration framework
The pathway is anchored in the Drug Registration Management Measures (Order No. 27, effective 2020), which established conditional approval as one of the expedited procedures for clinically valuable drugs and specified that conditionally approved products carry "corresponding time limits" for completing post-marketing work and "corresponding handling measures," up to revocation of the drug registration certificate, if those limits are missed 7879. NMPA Announcement No. 82 of 2020 then issued the operating trial procedures for breakthrough therapy, conditional marketing authorization, and priority review applications as a package, formally linking conditional approval to the other expedited routes 73.
These pathways are complementary rather than mutually exclusive. NMPA's own policy data illustrate the overlap: of 115 applications taken into the Priority Review and Approval Procedure in 2021, 41 met the criteria for conditional approval, so a large share of priority-review oncology and rare-disease products reach the market through the conditional route 69. Products in these tracks also receive structured CDE communication and, in some cases, may file supplementary applications after launch 76.
Eligibility criteria
CDE/NMPA guidance frames conditional approval as reserved for innovative drugs treating serious or life-threatening diseases with an unmet need, including rare diseases, where the applicant can commit to later confirmation 1. A drug may qualify when it is:
- Intended for a serious or life-threatening disease with no effective treatment available, or otherwise addressing a clear unmet clinical need 1.
- A new drug meant to prevent or treat serious disease, or to slow progression to a more severe stage, including for rare diseases 1.
- A product entering a space where treatments already exist but that still meets unmet-need criteria, such as clearly better outcomes in serious disease than existing therapies, benefit in patients intolerant of or unresponsive to current options, useful combination potential, comparable efficacy with less toxicity or better adherence, or response to a newly emerging public health need 1.
The guidance also extends the pathway to rare-disease drugs already approved overseas, allowing the overseas approval dataset to support a conditional authorization in China 1.
Evidence that can support a conditional approval
The evidentiary standard is that the data must reasonably predict clinical benefit, rather than having already demonstrated it in full 1. The guidance recognizes three broad categories of supporting evidence:
- Surrogate endpoints that are highly likely to predict clinical benefit. A surrogate is a biomarker or other measure that does not directly capture clinical benefit but can predict it, and the applicant must show the prediction rests on both biological plausibility and empirical evidence 1.
- Intermediate clinical endpoints that show benefit earlier and reasonably predict longer-term outcomes, provided they demonstrate a significant advantage over existing treatments. The guidance offers multiple sclerosis as an example: routine approval might require two years of observation, while conditional approval could rest on an intermediate endpoint read at one year 1.
- Early or mid-phase clinical trial data, where clinical benefit can be reasonably predicted and there is a significant advantage over existing treatments 1.
For anti-tumor drugs specifically, CDE guidance is explicit that in advanced malignancies without standard treatment, single-arm studies with objective response rate (ORR) as the primary endpoint can support (conditional) marketing approval, but ORR is only preliminary evidence of anti-tumor activity and does not necessarily reflect survival 53. CDE therefore expects early trials to collect additional clinical-benefit indicators alongside ORR 53. Where a marketing application rests on a single-arm ORR study, CDE expects, at minimum, two independent efficacy assessments of all protocol-specified and enrolled patients plus all safety data at initial submission, rolling submission of continued efficacy and safety data for at least six months after the last patient enrolls during NDA review, and all protocol-specified efficacy and safety data before approval 54.
More broadly, CDE's anti-tumor framework treats overall survival (OS) and quality of life as the principal efficacy endpoints, with tumor shrinkage or sustained stabilization as prerequisites 97. Progression-free survival (PFS), together with TTP, RFS and DFS, is treated as a recognized surrogate endpoint, and ORR as a secondary endpoint; when PRO, PFS or ORR are used, randomized and blinded designs are expected to characterize efficacy 9757.
Post-approval confirmatory requirements
Conditional approval is explicitly not the end of development. The guidance requires the applicant to develop a confirmatory trial protocol and timeline as early as possible, and at the time authorization is granted the applicant should already have agreed the confirmatory protocol with the regulator and begun implementing it; if implementation has not started, the applicant must provide sufficient justification 1. Trials based on intermediate endpoints or early/mid-phase data must be completed according to the agreed protocol 1. For overseas-approved rare-disease drugs, the holder must complete ethnic-difference (racial difference) trials and other required studies as soon as possible after conditional approval 1.
For oncology, CDE expects the confirmatory endpoint to be clinical-benefit evidence, generally prolonged OS or another established predictor of benefit, rather than continued reliance on ORR alone 55. Confirmatory studies should use randomization and blinding where ethically permissible, with survival follow-up rationally scheduled (for example at least every three months in relevant oncology studies) 57.
Failure to deliver has defined consequences. NMPA may revoke a conditional approval where the confirmatory trial fails to verify the predicted benefit, other evidence shows a lack of safety or efficacy, the holder fails to diligently conduct the required post-approval studies, or false or misleading promotion is disseminated 1. This mirrors the Order No. 27 provision that conditionally approved products carry completion time limits and that missing them can lead to revocation of the registration certificate 78.
The 2026 tightening of the procedures
NMPA revised the operating procedures in 2026. Announcement No. 41 of 2026 issued a revised "Procedures for Review and Approval of Conditional Drug Marketing Approval Applications," with the stated purpose of further strengthening supervision and management of conditional approvals, effective on issuance 72. It sets out how holders manage lapsed obligations: a holder whose registration certificate has expired and who needs an extension of the study, or a change to the confirmatory study protocol, may file the corresponding registration application, and such applications had to be submitted within three months of the announcement 72. Separately, Announcement No. 3 of 2026 allows applicants to request Category I communication on priority-review and conditional-application matters for urgently needed overseas-marketed drugs, and requires a post-marketing risk control plan that includes post-marketing clinical research plans and supporting benefit-risk materials 7071. The direction of travel is clearer accountability for the post-approval commitments that justify early access.
Oncology products granted conditional approval
The NMPA review reports (审评报告) mark conditional status directly with the field "附条件批准: 是". The examples below are products the review reports explicitly flag as conditional approvals, spanning single-arm ORR filings, PFS-based combinations, and CAR-T cell therapies.
| Product | Applicant/holder | Indication | Approval basis | Post-approval position |
|---|---|---|---|---|
| Selinexor tablets (塞利尼索片) | Antengene (Zhejiang) Pharmaceutical Technology | Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines, single agent | Single-arm data from ATG-010-DLBCL-001 / SEARCH 99 | Marked conditional; specific confirmatory requirement not stated in the report excerpt 99 |
| Golixitinib capsules (戈利昔替尼胶囊) | Dizhe (Jiangsu) Pharmaceutical; Shanghai Hequan | Relapsed/refractory peripheral T-cell lymphoma (PTCL) after ≥1 prior therapy, single agent | International multicenter phase II single-arm pivotal study agreed with CDE 100 | Marked conditional; an ongoing confirmatory trial is referenced in the development history 100 |
| Sintilimab injection (信迪利单抗) | Innovent Biologics (Suzhou) | EGFR-mutant locally advanced/metastatic non-squamous NSCLC after EGFR-TKI failure, with bevacizumab + pemetrexed + cisplatin | ORIENT-31 study evidence 105 | Marked conditional; confirmatory requirement not detailed in the report excerpt 105 |
| Penpulimab injection (派安普利单抗) | Chia Tai Tianqing Kangfang (Shanghai); Zhongshan Kangfang | First-line recurrent/metastatic nasopharyngeal carcinoma, with gemcitabine + cisplatin | Randomized, double-blind AK105-304 study: median PFS 9.8 vs 7.1 months, HR 0.51 101 | Marked conditional; post-approval requirement recorded as "none" (无) 101 |
| Axicabtagene ciloleucel injection (阿基仑赛注射液) | Fosun Kite Biotechnology | First-line-refractory or early-relapsing adult large B-cell lymphoma | ZUMA-7 pivotal data plus ZUMA-1, Chinese bridging study FKC876-2018-001, and Chinese real-world study FKC876-2020-001 103 | Marked conditional; holder to provide more efficacy and safety data post-launch 103 |
| Relmacabtagene autoleucel injection (瑞基奥仑赛注射液) | Shanghai/Suzhou JW Therapeutics (药明巨诺) | Relapsed/refractory follicular lymphoma (grade 1/2/3a) after ≥2 lines | China open-label study JWCAR029-002 104 | Marked conditional; longer-term efficacy data to come from post-marketing study 104 |
| Aponermin for injection (注射用埃普奈明) | Wuhan Haite Biopharmaceutical | Relapsed/refractory multiple myeloma after ≥2 prior therapies, with thalidomide + dexamethasone | Met conditional-approval criteria; single-agent efficacy/safety dataset 107108 | Post-market requirement recorded as "none" (无); a post-market risk management plan and effectiveness research are noted 108 |
The set illustrates the recurring pattern. Most conditional oncology approvals sit in later-line or biomarker-defined populations where a single-arm ORR readout or an interim PFS advantage was accepted as reasonably predicting benefit, with the holder expected to mature the confirmatory evidence, generally survival-oriented, after launch. Recording "none" for a post-approval requirement in a report (as with penpulimab and aponermin) reflects that the pivotal package itself was considered adequate for the conditional grant, not that the product escapes the pathway's general post-marketing accountability.
What this means in practice
For sponsors, the pathway rewards early engagement: the confirmatory protocol and timeline are expected to be agreed with CDE, and ideally underway, by the time conditional approval is granted, not negotiated afterward 1. The evidentiary bar is "reasonably predicts clinical benefit," which in oncology usually means a defensible surrogate (ORR in a single-arm setting, or PFS in a randomized combination) paired with a credible plan to confirm survival or another clinical-benefit endpoint 5355. And the obligation is enforceable: with the 2026 revisions, NMPA has sharpened its handling of confirmatory-study extensions, protocol changes, and lapsed certificates, and retains the ability to revoke approvals where confirmation fails or post-approval commitments are not met 721.